```json
{
"content": [
{
"type": "paragraph",
"content": "The prurigo nodularis treatment market focuses on therapies for a chronic, inflammatory skin condition characterized by severe itching and firm nodules, primarily affecting patients with underlying dermatologic or systemic comorbidities. With rising prevalence of chronic skin disorders and advancements in biologic therapies, this market holds strategic relevance in dermatology and rare disease sectors. The global prurigo nodularis treatment market size is projected to exceed $250 million by 2026, reflecting robust industry expansion driven by unmet clinical needs and innovation in targeted treatments."
},
{
"type": "paragraph",
"content": "The market is expected to grow at a compound annual growth rate (CAGR) of 8.5–9.2% from 2026 to 2033, fueled by increasing adoption of biologics such as IL-31 antagonists and JAK inhibitors, as well as regulatory support for orphan drug designations. Key macro drivers include heightened patient awareness, expanding geriatric populations at higher risk, and rising healthcare expenditure in emerging economies. North America remains the largest regional market, while the Asia-Pacific region is the fastest-growing due to improving diagnostic infrastructure and therapeutic accessibility. Emerging therapies and personalized treatment strategies are poised to redefine the competitive landscape over the forecast period."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Biologics", "Small Molecules", "Topicals"],
"periods": ["2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[45, 50, 58, 67, 76, 86, 98, 110], // Biologics
[30, 33, 37, 42, 48, 54, 60, 67], // Small Molecules
[15, 17, 19, 21, 23, 25, 27, 29] // Topicals
]
}
}
]
}
```
